Today: 8 June 2026
Browse Category

Biotechnology 30 December 2025 - 2 January 2026

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

Intelligent Bio Solutions shares fell 12.1% to $8.38 in late morning trading after announcing a $10 million private placement with two tranches of warrants. The deal, priced at $4.35 per share and warrant, follows a manufacturing partnership with Syrma Johari MedTech aimed at cutting costs and boosting margins ahead of a planned 2026 U.S. launch.
2 January 2026
··
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics shares closed 2025 up 3.5% at $63.54 after FDA cleared Myqorzo for obstructive hypertrophic cardiomyopathy. The drug, set to launch in January under a REMS program and boxed warning, will compete with Bristol Myers Squibb’s Camzyos. Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 each on Dec. 29 under a pre-arranged plan. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
····
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome Therapeutics shares surged 22.9% to $182.64 after the FDA granted priority review to its application for AXS-05 in treating agitation in Alzheimer’s disease, setting an April 30 decision date. The company also plans to file for approval of AXS-12 for cataplexy in narcolepsy this month, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
1 January 2026
··
INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

Intelligent Bio Solutions shares jumped 132% to $9.53 before dropping 14% after-hours as the company announced a $10 million private placement and a new manufacturing deal with Syrma Johari MedTech. The placement, priced at $4.35 per share and warrants, is set well below the closing price. Volume hit 108 million shares. The company recently enacted a 1-for-10 reverse split after a Nasdaq minimum bid warning.
1 January 2026
··
BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne shares fell 4% to $81.61 in thin trading on the last day of 2025, underperforming diagnostics peers. The company last reported third-quarter revenue of $83.5 million, up 117% year over year, and forecast full-year revenue of $293 million to $299 million. No new company disclosures appeared Wednesday. Management is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
31 December 2025
··
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics shares climbed 3.7% to $63.63 Wednesday, bucking a weaker market as investors awaited Myqorzo’s U.S. launch in January. A Form 4 showed Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 on Dec. 29 under a pre-set plan. The drug, approved this month, will be distributed with a REMS safety program. Investors are watching for pricing details and initial uptake.
31 December 2025
··
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

Intelligent Bio Solutions shares jumped 160% to $10.66 after announcing a manufacturing deal with Syrma Johari MedTech to scale production of its fingerprint drug-screening device. The company expects over 40% annual production cost savings and a 20-point gross margin boost. Trading volume hit 48.13 million shares, far above average. The stock traded between $5.62 and $11.52 after closing at $4.10 Tuesday.
31 December 2025
··
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio shares jumped 6.7% Monday, closing at $165.29 after trading as high as $169.75, with volume topping 309,000 shares. The move follows Dec. 1 trial results showing its oral drug tinlarebant met the main goal in Stargardt disease, and a $154-per-ADS public offering. No new company news has emerged since then. Traders are watching if gains hold as the stock trades above its recent offering price.
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
1 … 6 7 8 9 10 … 18

Stock Market Today

  • Howard Hughes Holdings (HHH) Stock Analysis Reveals Potential Undervaluation
    June 8, 2026, 3:42 AM EDT. Howard Hughes Holdings (HHH) shares recently closed at $65.13, down 34% over five years but gaining 3.6% last week. A Discounted Cash Flow (DCF) analysis, which forecasts future cash flows to estimate stock value, indicates a fair value of $101.15 per share. This suggests HHH is undervalued by 35.6% compared to its current price. The company reported a free cash flow of $437.2 million over the last twelve months, projected to rise to $625.994 million by 2030. Despite mixed share performance, this valuation implies potential for investors seeking opportunities in the real estate management and development sector.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop